| US 7,476,682 B2 | ||
| N-substituted piperidine derivatives as serotonin receptor agents | ||
| Carl-Magnus Andersson, Hjärup (Sweden); Nathalie Schlienger, Frederiksberg (Denmark); Alma Fejzic, Frederiksberg (Denmark); Eva Louise Hansen, Højby (Denmark); and Jan Pawlas, Frederiksberg (Denmark) | ||
| Assigned to Acadia Pharmaceuticals, Inc., San Diego, Calif. (US) | ||
| Filed on May 03, 2006, as Appl. No. 11/417,866. | ||
| Application 11/417866 is a continuation of application No. 11/299566, filed on Dec. 12, 2005. | ||
| Prior Publication US 2006/0199818 A1, Sep. 07, 2006 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/453 (2006.01); A61K 31/4523 (2006.01) | ||
| U.S. Cl. 514—326 [514/318; 514/320; 435/7.2] | 50 Claims |
1. A method of inhibiting an activity of a 5HT2A receptor comprising contacting the 5HT2A receptor with an amount of one or
more of the compounds of Formula I that is effective in inhibiting the activity of the 5HT2A receptor, wherein the compound
of Formula I has the structure:
 R1 is an optionally substituted heterocyclyl;
R2 and R3 are independently selected from the group consisting of hydrogen, C1-6-alkyl and halogen or such that R2 together with R3 forms a 3-, 4-, 5-, 6-, 7-membered ring system with the atoms of the piperdinyl ring;
m is 1;
n is selected from the group consisting of 1, 2, and 3;
Ar1 is an optionally substituted aryl or heteroaryl;
W is selected from the group consisting of oxygen and sulfur;
X is selected from the group consisting of optionally substituted methylene, optionally substituted ethylene, optionally substituted
propylene, optionally substituted vinylene, and CH2N(RN), wherein RN is selected from hydrogen and C1-6-alkyl; and
Ar is an optionally substituted aryl or heteroaryl.
|